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Abstract
Background: Pathophysiological mechanisms involved in amyotrophic lateral sclerosis (ALS) are complex and none has
identified reliable markers useful in routine patient evaluation. The aim of this study was to analyze the CSF of patients with
ALS by
1H NMR (Nuclear Magnetic Resonance) spectroscopy in order to identify biomarkers in the early stages of the
disease, and to evaluate the biochemical factors involved in ALS.
Methodology: CSF samples were collected from patients with ALS at the time of diagnosis and from patients without
neurodegenerative diseases. One and two-dimensional
1H NMR analyses were performed and metabolites were quantified
by the ERETIC method. We compared the concentrations of CSF metabolites between both groups. Finally, we performed
principal component (PCA) and discriminant analyses.
Principal Findings: Fifty CSF samples from ALS patients and 44 from controls were analyzed. We quantified 17 metabolites
including amino-acids, organic acids, and ketone bodies. Quantitative analysis revealed significantly lower acetate
concentrations (p=0.0002) in ALS patients compared to controls. Concentration of acetone trended higher (p=0.015), and
those of pyruvate (p=0.002) and ascorbate (p=0.003) were higher in the ALS group. PCA demonstrated that the pattern of
analyzed metabolites discriminated between groups. Discriminant analysis using an algorithm of 17 metabolites revealed
that patients were accurately classified 81.6% of the time.
Conclusion/Significance: CSF screening by NMR spectroscopy could be a useful, simple and low cost tool to improve the
early diagnosis of ALS. The results indicate a perturbation of glucose metabolism, and the need to further explore cerebral
energetic metabolism.
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Introduction
Amyotrophic lateral sclerosis (ALS), the most common adult-
onset motor neuron disease, is characterized by degeneration of
both lower and upper motor neurons leading to death within 2–5
years of onset [1]. Although the underlying causes of motor
neuron degeneration are still unknown, hypotheses suggest a role
for oxidative stress, mitochondrial dysfunction, glutamate-
mediated excitotoxicity, cytoskeletal abnormalities, and protein
aggregation [2].
The lack of biological tools to diagnose ALS together with the
non specificity and heterogeneity of clinical symptoms lead difficulty
in making the diagnosis in very early stages. Indeed, the time
between the appearance of first symptoms and the diagnosis is often
9 monthsormore[3].Several authorshavestudiedthepotentialuse
of blood and cerebrospinal fluid (CSF) biomarkers associated with
ALS but these studies were limited to small numbers of target
molecules supposed to be linked to ALS pathogenesis [4,5,6]. While
many in vivo studies have provided clues to pathogenesis
mechanisms, none has identified reliable markers useful in routine
patient evaluation. Recently, high-throughput techniques such as
metabolomics have been used to evaluate a combination of markers
in patients with neurological diseases [7]. Metabolomic studies have
been performed via different analytical methods such as high
performance liquid chromatography followed by electrochemical
detection [8] or high resolution
1H NMR (Nuclear Magnetic
Resonance) spectroscopy [9]. NMR spectroscopy appears to be
cost-effective, useful in routine care, and screening [10]. Different
kinds of biological fluids have been screened [11], but CSF may
have the highest yield of biomarkers in ALS because of its direct
contactwith the brain,itsaccessibility,and itsdynamicchangeswith
the cerebral environment.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13223The aim of this study was to search for a metabolic signature of
ALS in the CSF using high resolution NMR spectroscopy. We
compared
1H NMR spectra of CSF samples collected from ALS
patients and from patients without a neurodegenerative disease.
Methods
Patients and controls
Cerebrospinal fluid samples were obtained at the time of
diagnosis from patients in three French ALS centers (Tours, Lille
and Paris). The diagnosis of ALS was made according to
diagnostic criteria for definite or probable ALS based on the El
Escorial World Federation diagnostic criteria [12]. In routine
practice, a CSF analysis is performed in all patients in whom a
diagnosis of ALS is suspected. All patients involved in our study
gave informed consent. Patients from Lille and Paris gave written
consent to perform research with their CSF samples. In routine
practice, a CSF analysis is performed in all patients in whom a
diagnosis of ALS is suspected. For our study, we used a part of
CSF sample to perform complementary analysis with NMR. In
Tours, before starting this study, we asked our local ethics
committee about the requirement of informed consent. We
obtained verbal permission from the Persons Protection Commit-
tee’s President of Tours to use CSF samples obtained by routine
check up and without written consent of patients and controls.
Patients from Tours gave verbal consent to use their CSF samples
for medical research. One of the clinicians was responsible to give
to patients the appropriate information about the use of their CSF
samples in medical research. Ethics committees approved consent
procedure.
For each patient, information on diagnosis, gender, age, site-of-
onset and age-at-onset were obtained. The site-of-onset was
defined as either bulbar or limb-onset. The age-at-onset was
defined as the time at which motor weakness was first noted by the
patient. We compared clinical, demographic data and biological
parameters of ALS patients between each center. According to
ethical considerations, it is not conceivable to collect CSF from
healthy subjects. Then, the control group encompassed individuals
with non-neurodegenerative diseases having a routine lumbar
puncture at the time of diagnosis. Standard clinical laboratory tests
including bacteriological, biochemical analyses of CSF and blood
glucose levels were collected for each subject.
Sample preparation
CSF samples were stored in polypropylene tubes at 280uC
immediately after collection and until analysis [13]. Before the
NMR experiments, samples were thawed, and centrifugated at
3000g for 5 minutes. Then 0.5 mL of CSF were mixed with
0.1 mL of deuterium oxyde solution to calibrate the NMR
spectrometer. Final adjustment of pH to 9.560.15 was done with
HCl or NaOH solutions using a pH-meter equipped with a glass
combination electrode. Finally, 0.6 mL of the prepared solutions
were transferred to a 5-mm NMR tube (CortecNet, Paris, France)
for
1H NMR analysis.
Magnetic Resonance Spectroscopy experiments
The
1H NMR spectra were performed on a Bruker DRX-500
spectrometer (Bruker SADIS, Wissembourg, France), operating at
11.7 T, with a Broad Band Inverse (BBI) probehead equipped with
Z gradient coil. NMR measurements were done at 298K, with
non-spinning samples. CPMG
1H NMR spectra were recorded
with a spin-spin relaxation delay of 80ms (echo time 200 ms
repeated 200 times), collected with 128 transients, eight dummy
scans and a d1 of 10s into 32k data points with a spectral width of
7500 Hz and an acquisition time of 2.04s. The water peak was
irradiated during d1 delay. Unambiguous assignments were
performed using a two-dimensional correlation spectroscopy.
Eight transients per increment and 256 increments were collected
into 4K data points. COSY spectra were acquired with 3s
relaxation delay, 6000Hz spectral width in both directions. The
water signal was irradiated during the recycling time. Shimming of
the sample was performed automatically on the water signal. For
quantification of metabolite peaks, the electronic reference
(ERETIC) signal was set during acquisition time [14]. The
ERETIC pulse was generated by a second radio frequency
channel phase-synchronized with the NMR signal of the sample.
ERETIC intensity, frequency and line broadening were calibrated
with a reference tube to determine metabolite concentrations.
Data were processed using XWinNMR version 3.5 software
(Bruker Daltonik, Karlsruhe, Germany). Prior to Fourier trans-
formation (FT), the 1D FIDs were zero-filled to 64K data points
which provided sufficient data points for each resonance, and a
line broadening factor of 0.3Hz was applied. All spectra were
corrected for phase distortion and the baseline was manually
corrected for each spectrum. Each spectrum was integrated using
WinNMR software integral function.
Quantification of metabolite peaks was performed with the
ERETIC peak as a quantitative reference. Calibration of the
ERETIC peak, which had the same area in all spectra, was made
using a mixture of 9.13mM of citrate, 9.20mM of lactate, and
9.10mM of glutamate as the reference tube. According to this
reference tube, the measured area of the ERETIC peak (AE)
symbolized a calculated concentration (CE) of 4,67mM. Metab-
olite concentration (CX) was calculated according to the following
formula:
CX~½(AX   CE)=(NX   AE)   fD
where Cx is the metabolite concentration in the CSF sample, Nx is
the number of protons of the quantified peak metabolite, CE is the
calculated concentration for the ERETIC peak, AE is the
ERETIC area peak, and fD is the dilution factor of the CSF
sample.
Spectral
1H assignments were achieved according to the
literature values of chemical shifts in various media and biofluids
[15]. Because beta-methyl-L-amino-alanine (BMAA) has been
recently reported by several authors as potentially involved in the
etiology of ALS, we searched for its presence [16].
Statistical analysis
Univariate data analysis. A comparison of CSF
concentrations between ALS and non ALS patients was done to
highlight the potential disturbances in the metabolic pathway due
to ALS.
We compared concentrations of CSF metabolites between ALS
and non ALS patients using t-tests or Wilcoxon tests. Among the
53 metabolites identifiable in CSF by NMR [17], we quantified
(by XWin NMR software) those having the highest signal, i.e
quantifiable with the highest accuracy.
A correction for multiple tests was applied to adjust the p values
by accounting for the 17 metabolites evaluated in the analysis.
Differences were considered as significant when p,0.003.
Statistical analysis was performed with JMP statistical software
version 7.0.2 (SAS Institute, Cary, North Carolina).
Multivariate data analysis. Principal component analysis
(PCA) was performed using SPAD
 software (SPAD v5.6 software
decisia, France). PCA is a descriptive multivariate analysis that
rapidly identifies groups of samples according to their scores in
Metabolomics of CSF in ALS
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reduced to a series of principal components (PC), each
representing correlated spectral changes and summarized in a
score plot. PCs are new variables that are orthogonal to each other
and explain progressively less variance in the data set. PCs were
displayed in a two- dimensional score plot, allowing visualization
of the distribution and grouping of the samples in the new variable
space.
Discriminating analysis was performed to evaluate how closely a
set of measurement metabolites predict the classification of ALS
and non ALS patients. Thus, we randomly divided our data into a
training set of size 50 and a test set that consisted of the remaining
patients. The model was built based on the training set with known
clinical status to construct a set of linear functions of the measured
metabolites. The clinical status was predicted from the test group
to evaluate the power of prediction.
Statistical analysis was performed with JMP statistical software
version 7.0.2 (SAS Institute, Cary, North Carolina) and R version
2.8.0, an open source program developed by the R Foundation for
Statistical Computing (Vienna, Austria).
Results
Patients and controls
Clinical data and CSF samples were obtained from 50 patients
with ALS (22 from Tours, 19 from Lille and 9 from Paris) and 44
controls. No differences in clinical, demographic or biological data
were found between patients from Tours, Lille and Paris, so we
pooled these samples into a single group: the ALS group. 61% of
ALS patients were male and had median age-at-onset of 62.5 years
(22.9–90.6). 65% of ALS patients had limb-onset. The control
group encompassed patients with the following diseases :
sarcoidosis (one patient), psychiatric disorders (three patients),
cerebellar syndrome (one patient), peripheral neuropathy (thirteen
patients), chronic inflammatory demyelinating polyneuropathy (six
patients), muscular cramps (one patient), facial paralysis (one
patient), traumatic cerebral injury (one patient), ataxia with axonal
neuropathy (one patient), normal pressure hydrocephalus (two
patients), paresthesia (two patients), epileptic seizures (one patient),
spinal cord infarction (one patient), cervical spondylotic myelop-
athy (three patients), adrenomyeloneuropathy (one patient), non-
organic hypoesthesia (one patient), neuroborreliosis (one patient),
dystonia (one patient), Hallervorden-Spatz syndrome (one patient),
non neurologic deafness (one patient), and oculomotor paralysis
(one patient). Controls were matched with ALS patients by age
and sex. There were no differences in standard bacteriological and
biochemical tests of CSF, or in blood glucose levels between
groups (Table 1).
Qualitative
1H-NMR analysis and identification
The
1H-NMR signals of all common metabolites including
amino-acids, organic acids, and carbohydrates were assigned
according to previous publications. [17]. Qualitative analysis of
CSF by superimposition of spectra from ALS patients and controls
did not reveal any differences in metabolite composition.We found
particularly no trace of BMAA in the CSF of our ALS patients.
Accurate visual comparison of the spectra was difficult because of
dilution factor. An example of CSF spectra from a typical ALS
patient and control are shown on figure 1.
Univariate data analysis
We analysed 17 CSF metabolites in ALS and non ALS patients,
defined as follows: amino-acids (alanine, glutamine, tyrosine),
organic acids (citrate, acetate, a-hydroxybutyrate (AHBT)), ketone
bodies (b-hydroxybutyrate (BHBT), acetone, acetoacetate), glu-
cose, fructose, metabolites involved in glucose metabolism
(pyruvate, lactate, creatinine and creatine, recently identified as
markers of mitochondrial dysfunction [18], the anti-oxidant
molecule ascorbate, and formate as well as ethanol.
Results of quantitative analyses of metabolites in CSF from ALS
patients and controls are presented in table 2. We noted 3
metabolites for which mean CSF concentrations were significantly
different between groups (p,0.003). We found significantly lower
concentrations of acetate in ALS patients than in controls (53 vs
104 mmol/L, p=0.0002). There were higher concentrations of
ascorbate and pyruvate in ALS patients compared to non ALS
patients (p=0.003 and p=0.002, respectively). The lactate/
pyruvate ratio, a marker of cytosolic oxido-reduction state was
lower in ALS patients than in controls (56 vs 115, p=0.0029).
Acetone concentrations trended to be higher in ALS patients
(p=0.015). Box plots representing acetate, acetone, ascorbate, and
pyruvate concentrations in the ALS and non ALS groups are
shown in figure 2.
PCA of the
1H-NMR metabolite differences between ALS
and non-ALS patients
PCA analysis was applied to the NMR data using the 17
metabolites integrated in all patients. The resulting PCA score plot
is shown in figure 3, with the two first PCs explaining 55.65% of
the variation in the selected metabolites. The PCA scores plot for
the quantitative NMR data showed separated clusters for ALS and
non ALS patients. Each spectrum can be viewed as an observation
in PCA space where the proximity of observations represents the
similarity of the metabolic profiles of CSF samples. The PCA score
plot shows the metabolites contributing to the separation of the
two clusters and allows the identification of metabolites acting on
this clustering. The ALS patients seemed to be characterized by
high concentrations of pyruvate, ascorbate, and acetone whereas
the non-ALS group seemed to be weighted by lower concentra-
tions of these metabolites and by high concentrations of formate,
acetate and b-hydroxybutyrate.
All metabolites were entered into the discriminant model.
According to this panel of metabolites, we evaluated the clinical
status of patients and identified that they were predicted in the
correct group with a probability evaluated at 81.6%.
Table 1. ALS and non ALS patients characteristics.
ALS patients
(n=50)
non ALS patients
(n=44) p
Sex
Male 31 (62%) 27 (61%) 1.00
Female 19 (38%) 17 (39%)
Age 64.6 (35.0–90.6) 60.6 (26.8–82.9) 0.20
Blood
Glucose (mmol/L) 5.3 (4.4–7.0) 5.9 (4.8–9.0) 0.11
LCR
Leucocytes/mm
3 1 (0–50) 1 (0–75) 0.32
Cell/mm
3 0 (0–2200) 1 (0–75) 0.80
Protein (g/L) 0.43 (0.33–1.08) 0.45 (0.24–6.23) 0.89
Glucose (mmol/L) 3.3(0.56–7.16) 3.2 (0.15–8.9) 0.51
Data are expressed in median (range).
doi:10.1371/journal.pone.0013223.t001
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Metabolomic studies are a powerful approach to ascertaining
metabolic signatures from a combination of small molecules in
biological fluid and could lead to the identification of diagnostic or
prognostic biomarkers. NMR spectroscopy is a non-invasive
technique, needs little sample preparation and gives an overview
of the principal metabolic pathways. To our knowledge, the
present study is the first to address the potential use of
1H NMR
spectroscopy in analysing CSF from ALS patients.
We compared CSF metabolic profiles between ALS and non-
ALS patients. First, we conducted a qualitative analysis to measure
any qualitative difference between groups. Among the 17
metabolites measured in our study, 13 were also analysed by
Kumar et al. in serum samples of ALS patients [9], and we
detected the same metabolites and in the same range as that
reported in a previous study of human CSF metabolome [17].
Importantly, glutamate could not be detected in CSF of patients
and controls by NMR technique. Fiszmann in a recent study [19]
found a glutamate concentration around 0.6–0.9 mM in control
CSF and 2.6–6.1 mM in ALS CSF. Even if there may be an
increase of glutamate in ALS patients, the NMR methodology is
not able to pick up such very low concentrations.
Univariate analysis showed higher concentrations of CSF
ascorbate in ALS patients. Two previous studies have compared
concentrations of ascorbate between ALS patients and controls but
results were contradictory [20–21]. The elevated levels of this anti-
oxidant molecule are compatible with oxidative stress previously
described in ALS and could also be linked to ascorbic acid release
from astrocytes after glutamate stimulation [22,23]. Glutamate-
mediated excitotoxicity is a recognized factor in the pathophys-
iology of ALS and could result in elevated levels of ascorbic acid.
Ascorbic acid might, by itself, modulate neuronal metabolism
through inhibition of glucose consumption during episodes of
glutamatergic synaptic activity and by stimulating lactate uptake in
neurons [23,24], observations consistent with the lower lactate/
pyruvate ratio seen in our ALS patients. These findings together
with data previously published on metabolic modifications suggest
a perturbation of brain glucose metabolism in patients with ALS
[11].
We also noted lower CSF concentrations of acetate and a trend
toward higher CSF concentrations of acetone in ALS patients. We
found no differences in other ketone bodies between ALS patients
and controls, but did note high interindividual variability of these
parameters. Kumar et al. described higher concentrations of
Figure 1. CSF spectra by
1H NMR from ALS patient (A) and non ALS patient (B).
doi:10.1371/journal.pone.0013223.g001
Table 2. CSF metabolite profiles in ALS and control subjects
measured by
1H NMR spectroscopy.
Metabolites (mmol/L) ALS (n=50) Non ALS (n=44) p
AHBT 61 (0–137) 59 (0–177) 0.17
Ethanol 24 (0–170) 24 (0–460) 0.29
Alanine 56 (6–596) 61 (0–214) 0.74
Acetate 53 (9–389) 104 (2–366) 0.0002
BHBT 17 (4–85) 27 (0–134) 0.97
Lactate 2076 (444–3892) 2020 (94–5322) 0.81
Acetoacetate 9 (0–29) 8 (0–29) 0.89
Acetone 11 (0–59) 5 (0–23) 0.015
Glutamine 716 (139–1272) 785 (35–1296) 0.24
Pyruvate 68 (3–128) 17 (0–201) 0.002
Citrate 283 (22–49) 285 (12–754) 0.51
Creatine/creatinine 155 (25–316) 160 (9–450) 0.65
Glucose 3240 (560–7166) 3174 (150–8928) 0.98
Fructose 428 (0–1224) 419 (0–967) 0.82
Ascorbate 25 (0–152) 0 (0–165) 0.003
Tyrosine 12 (0–48) 8 (0–117) 0.35
Formate 28 (3–91) 30 (1–187) 0.35
Data are expressed in median and range. P value inferior to threshold after
correction for multiple test (p=0.003) are shown in bold.
AHBT: Alphahydroxybutyrate.
BHBT: Betahydroxybutyrate.
doi:10.1371/journal.pone.0013223.t002
Metabolomics of CSF in ALS
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13223ketone bodies (BHBT and acetone) and acetate in the serum of
ALS patients [9]. Based on the energetic metabolism in brain
compared to the blood compartment, Kumar’s results do not
necessarily contradict our own. Hypermetabolism described in
ALS patients may lead to increased energy requirements in muscle
and brain [25,26]. Consequently, in addition to the usual energetic
substrates (carbohydrates, lactate, fat), ketone bodies and acetate
could also be used as a source of energy in the brains of ALS
patients [27,28]. Thus the high levels of ketone bodies and acetate
reported in serum could be due to the increased beta oxidation of
fatty acids, related to higher energy needs [9,29]. Monocarboxylic
acid transporters (MCT1) mediate the transport of ketone bodies
and acetate from blood to brain through the Blood Brain Barrier
(BBB) and their influx into the brain is largely determined by the
amount of ketones and acetate present in the blood [27,30]. Thus,
acetate, acetoacetate and b-hydroxybutyrate may be consumed by
neurones and astrocytes to provide energy. However, metabolism
of acetone is different than for the other ketones, perhaps
explaining the still moderately higher level of acetone in ALS
patients [31].
Based on these data, we used two statistical approaches to assess
diagnostic consistency in ALS.
First, we performed the multivariate analysis PCA on the 17
metabolites detected by
1H NMR spectroscopy to provide a
metabolic signature for ALS. The scatter plot of PCA results
derived from the NMR spectra discriminated between ALS and
non-ALS populations. Of the metabolites responsible for the
observed separation on the PCA score plot, we found the same
discriminating metabolites as found using univariate analysis.
A discriminant analysis was performed to predict the classifi-
cation of ALS and non-ALS patients. The predictive power was
superior to 80%, sufficient to consider this panel of metabolites
useful in clinical practice. To our knowledge, Rozen et al. [8] were
the first and the only investigators to conduct a metabolomic study
using a multivariate approach. They studied perturbations of the
blood metabolome of 28 patients with motor neuron diseases
(MND) and 30 healthy controls using high performance liquid
chromatography. Of over 317 metabolites, they identified 50 that
were elevated in MND patients and 70 that were decreased
(p,0.05). Similar to our study, they separated MND patients from
controls using multivariate regression techniques.
This study demonstrates that
1H NMR spectroscopy combined
with multivariate analysis can detect changes in the concentrations
of some CSF metabolites in ALS, and highlights specific metabolic
pathway perturbations. Moreover to our knowledge, this study is s
the first to provide a diagnostic predictive power better than 80%.
However, the composition of CSF may not be the direct
consequence of metabolism in neurones and astrocytes, due in
part to the role of other independent factors such as BBB
transporters and release of metabolites from endothelial cells.
Despite the invasiveness of lumbar puncture, the benefits of a
correct diagnosis based on CSF component analysis may outweigh
the risk of the puncture procedure. [32] Future studies may reach
improved sensitivity and specificity by comparing blood and CSF
metabolites and discriminating the disturbances of metabolism in
blood from brain.
To our knowledge, this study is the first one reporting in CSF the
use of
1H NMR spectroscopy to explore metabolic pathways
Figure 2. Concentrations of different metabolites in ALS (n=50) and non ALS patients (n=44). CSF concentrations of pyruvate (A),
ascorbate (B), acetate (C) and acetone (D) are represented with median, upper and lower quartile, minimum and maximum data values.
doi:10.1371/journal.pone.0013223.g002
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studies and show promise that a biomarker panel could be
developed for helping in the early diagnosis of ALS. Further studies
with larger numbers of patients and controls, including other motor
neuron diseases, will be crucial to validate this model and to assure
its place in routine practice. It is also necessary to valid this panel of
biomarkers in another cross-sectional study with a separate
population, and of interest to perform a longitudinal study to
determine predictive power of this model on disease progression.
A better understanding of heterogeneous genetic, biochemical
and clinical features of ALS may help to define pathological
profiles among ALS patients. This study focuses on the NMR
profile, but we are aware that accuracy of early diagnosis of ALS
will depend on combination of several approaches like imaging,
electrophysiological and biological markers.
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